Results 91 to 100 of about 38,752 (185)

Analysis of VHH dynamics

, 2023
Vattekatte, Akhila, Diharce, Julien, Etchebest, Catherine, de Brevern, Alexandre   +3 more
openaire   +1 more source

Single oral dose of bovine Fc-fused single-domain antibody enables multi-week serum detectability in neonatal calves. [PDF]

Front Vet Sci
Yang S, Kim C, Moon J, Kim H, Hong S, Taufik IM, Kim J, Park S, Han J, Kim S.   +9 more
europepmc   +1 more source

Differential T cell reactivation by two PD-L1 nanobodies through blockade alone or blockade with internalization. [PDF]

Sci Rep
Lee JH, Cho SY, Lee HE, Lee S.
europepmc   +1 more source

From Phage Display to Yeast Secretion: Developing Fc-Fused Nanobodies Against Influenza Virus. [PDF]

Cells
Wang M, Li S, Li Y, Xia X, Zhang Y, Cao N, Li Y, Liu Y, Zhang S, Zhang L, Huang J.   +10 more
europepmc   +1 more source

Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager. [PDF]

Front Immunol
Wang H, Zhao R, Liu M, Jiang T, Sun D, Chi L, Huang Y, Lu Z, Yun Y, Wang X.   +9 more
europepmc   +1 more source

Controlled immobilization of single-domain antibodies using cellulose-binding modules for AB₅-type toxin detection in paper-based assays. [PDF]

RSC Adv
Belfakir SB, Jürgensen JA, Petersson M, Wraae MS, Munk P, Thumtecho S, Masteghin MG, Ljungars A, Laustsen AH, Thrane SW, Ross GMS.   +10 more
europepmc   +1 more source

Discovering novel therapeutic V_HHs for emerging viruses: perspectives from VEEV selection strategies. [PDF]

Front Immunol
LaPointe AT, Ferrara F, Zupancic JM, Montoya AL, Schmidt J, Hung LW, Kell AM, Velappan N.   +7 more
europepmc   +1 more source

Nanobody-based analysis of RhoGTPase stress response in <i>Schizosaccharomyces pombe</i>: Role of <i>mtl</i>2. [PDF]

Biotechnol Rep (Amst)
Rasheed N, Ali X, Ali T, Muhammad F, Rasheed MA.   +4 more
europepmc   +1 more source

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials. [PDF]

PLoS Med
Jansen E, Bockstal V, Herschke F, Olsson Gisleskog P, Rinaldi M, Boerboom A, Hadi S, Gaibu N, Moutschen M, Tersago D.   +9 more
europepmc   +1 more source

Balancing Multivalent Avidity and Receptor Availability Governs mRNA Delivery by Antibody-Functionalized Lipid Nanoparticles. [PDF]

Nano Lett
Hashiba K, Fukasaka M, Okuma C, Kobayashi-Ooka Y, Kajiwara K, Sugiyama A, Mizuno T, Shimomura Y, Maeda Y, Sasaki J, Enoki T, Hashino R, Mikuni S, Nishita H, Urushihara N, Ebe H, Yamada H.   +16 more
europepmc   +1 more source